

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09996954
Filing Date	2001-11-30
First Named Inventor	WAKSAL, HARLAN W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	1017.33537A.US3

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/A.H./	1	4863902		1989-09-05	Amagase, et al.	
/A.H./	2	4943533		1998-07-24	Mendelsohn, et al.	
/A.H./	3	5846565		1998-12-08	Brem, et al.	
/A.H./	4	5468754		1995-11-21	Hausheer, et al.	
/A.H./	5	5559235		1996-09-24	Luzzio, et al.	
/A.H./	6	5604233		1997-02-18	Hausheer, et al.	
/A.H./	7	5880133		1999-03-09	Hausheer, et al.	
/A.H./	8	6265411		2001-07-24	Thomas, et al.	

/Anne Holleran/

08/12/2008

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09996954	
	Filing Date		2001-11-30	
	First Named Inventor	WAKSAL, HARLAN W.		
	Art Unit	1643		
	Examiner Name	HOLLERAN, Anne L.		
	Attorney Docket Number	1017.33537A.US3		

/A.H./	9	5866572		1999-02-02	Baker, et al.	
/A.H./	10	5770599		1998-06-23	Gibson	
/A.H./	11	6140317		2000-10-31	Traxler, et al.	
	12					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/A.H./	1	20050112120		2005-05-26	Waksal	
/A.H./	2	20040057950		2004-03-25	Waksal	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/A.H./	1	EP 0 359 282 B1	EP		1995-05-24			<input type="checkbox"/>

/Anne Holleran/

08/12/2008

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09996954	
	Filing Date		2001-11-30	
	First Named Inventor	WAKSAL, HARLAN W.		
	Art Unit	1643		
	Examiner Name	HOLLERAN, Anne L.		
	Attorney Docket Number	1017.33537A.US3		

/A.H./	2	WO 96/40210 A	WO		1996-12-19		<input type="checkbox"/>
	3						<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/A.H./	1	Rockwell, P. et al., Molecular and Cellular Differentiation, 3(4):315-335, 1995	<input type="checkbox"/>
/A.H./	2	Fischer-Colbrie, J. et al, Anticancer Res. 17(1B): 613-619, 1997; ABSTRACT only	<input type="checkbox"/>
/A.H./	3	Turkeri, L.N., et al. Urology, 51(4): 645-649, 1998, Apr; ABSTRACT only	<input type="checkbox"/>
/A.H./	4	Modjtahedi, H. et al., British J. Cancer, 73: 228-235, 1996	<input type="checkbox"/>
/A.H./	5	Messa, C. et al. Acta Oncologica, 37(3): 285-289, 1998	<input type="checkbox"/>
/A.H./	6	Baselga et al., The epidermal growth factor receptor as a target for therapy in breast carcinoma, Breast Cancer Research and Treatment, Volume 29, pages 127-138 (1994)	<input type="checkbox"/>
/A.H./	7	Osband and Ross, Problems in the investigational study and clinical use of cancer immunotherapy, Immunotherapy , pages 193-195 Immunol. Today, 11(6): 193-195, 1990	<input type="checkbox"/>

/Anne Holleran/

08/12/2008

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09996954
	Filing Date		2001-11-30
	First Named Inventor	WAKSAL, HARLAN W.	
	Art Unit	1643	
	Examiner Name	HOLLERAN, Anne L.	
	Attorney Docket Number	1017.33537A.US3	

/A.H./	8	Antitumor Effects of Doxorubicin in Combination with Anti-epidermal Growth Factor Receptor Monoclonal Antibodies, J. Baselga, L. Norton, H. Masui, A Pandella, K. Coplan, W.H. Miller, Jr., J. Mendelsohn; Journal of the National Cancer Institute, Vol. 35, No. 16, 1327-1333 (1993)	<input type="checkbox"/>
/A.H./	9	Anti-tumor and Cell Cycle Responses on KB Cells Treatment with a Chimeric Anti-EGF-R Monoclonal Antibody in Combination with Cisplatin, M. Prewett, P. Rockwell, C. Rose, N.I. Goldstein, Immunology Department, Imclones Systems, Inc., International Journal of Oncology 217-224 (1996)	<input type="checkbox"/>
/A.H./	10	Abstract entitled Immunochemotherapy of Human Transitional Cell Carcinoma (TCC) with Anti-EGF-R Monoclonal Antibody (Mab) C225 and the Anti-cancer Drugs, Taxol and Cisplatin, AACR Annual Meeting, March 28-April 1998, New Orleans, LA	<input type="checkbox"/>
/A.H./	11	Inhibition of Human Tumor Growth in Nude Mice by a Conjugate of Doxorubicin with Monoclonal Antibodies to Epidermal Growth Factor Receptor, E. Aboud-Pirak, E. Hurwitz, F. Bellot, J. Schlessinger, M. Sela, Proc. Natl. Acad. Ser. USA., Vol. 86, pp. 3778-3781 (1989)	<input type="checkbox"/>
/A.H./	12	Role of Protein Tyrosine Kinase Receptors in Cancer: Possibilities for Therapeutic Intervention, P. Rockwell, N.I. Goldstein; Molecular and Cellular Differentiation 3 (4) 315-335 (1995)	<input type="checkbox"/>
/A.H./	13	Chin. J. Tuberc. Respir. Dis., Vol. 22, No. 3 (March 1999)	<input type="checkbox"/>
/A.H./	14	Chen Xiaodong, et al. The growth inhibition of anti-EGF receptor monoclonal antibody to human lung adenocarcinoma cells, Chin. J. Tuberc. Respir. Dis., Vol. 21, No. 4 (April 1998)	<input type="checkbox"/>
/A.H./	15	Natl. Med J. China, Vol. 78, No. 8 (August 1998)	<input type="checkbox"/>
/A.H./	16	Foreign Medical Sciences (Section of Immunology Foreign Medical Sciences), No. 2 (1993)	<input type="checkbox"/>
/A.H./	17	Foreign Medical Science: Stomatology, Vol. 22, No. 5 (September 1995)	<input type="checkbox"/>
/A.H./	18	Ren Xinling, et al., Mechanisms of anti-lung cancer activity for monoclonal antibody to epidermal growth factor receptor, J. Fourth Milit. Med. Univ., Vol. 18, No. 6 (1997)	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09996954
	Filing Date		2001-11-30
	First Named Inventor	WAKSAL, HARLAN W.	
	Art Unit	1643	
	Examiner Name	HOLLERAN, Anne L.	
	Attorney Docket Number	1017.33537A.US3	

/A.H./	19	Huang, S. et al., Proc. Amer. Assoc. Cancer Res., 40:421-422, March 1999; ABSTRACT only	<input type="checkbox"/>
/A.H./	20	Ciardiello, F., et al., Antihumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225, Clinical Cancer Res., Vol. 5, 909-916 (April 1999)	<input type="checkbox"/>
/A.H./	21	People's Republic of China, Request for Invalidation of a Patent Right, requested by Chen Chunhui, filed on April 17, 2007.	<input type="checkbox"/>
/A.H./	22	Prewett, M. et al., Growth inhibition of human pancreatic carcinoma in vitro and in vivo by chimeric anti-EGF receptor monoclonal antibody C225, Proc. Assoc. Cancer Res., Vol. 40, 730, March 1999.	<input type="checkbox"/>
/A.H./	23	Anderson, V. et al., Dose dependent pharmacokinetics of a chimerized monoclonal antibody against EGFr. Proc. Amer. Assoc. Cancer Res., Vol. 39, 523, March 1998	<input type="checkbox"/>
/A.H./	24	Prewett, M. et al., Growth inhibition of human renal cell carcinoma (RCC) cells in vitro and RCC xenografts in athymic mice by chimeric anti-EGF receptor monoclonal antibody C225, Proc. Amer. Assoc. Cancer Res., Vol. 39, 65, March 1998	<input type="checkbox"/>
/A.H./	25	Panek, R. et al., In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor, Journal of Pharmacology and Experimental Therapeutics., Vol. 283, No. 3 (December 1997).	<input type="checkbox"/>
/A.H./	26	Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts, Z. Fan, J. Baselga, H. Masui, J. Mendelsohn; Cancer Research, Vol. 53, 4637-4641 (1993)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Anne Holleran/	Date Considered	08/12/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.